Metastatic prostate cancer will kill 27,000 Americans in 2018. Reglagene’s Quadruplex Master Switch Technology enables the development of a new medicine that kills prostate cancer tumor cells. The National Cancer Institute notified Reglagene of a $300,000 STTR small business award on September 19. This award will provide Reglagene with the resources to ramp up its effort to translate groundbreaking research in telomerase biology from the University of Arizona onto a commercialization trajectory. The Principal Investigator on the award is Reglagene’s CSO, Dr. Laurence Hurley. Representing the University of Arizona is Dr. Andrew Kraft, Head of the Arizona Cancer Center and prostate cancer expert.